Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Oncology Institute Francisco Gentil

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

The Oncology Institute Francisco Gentil (popularly known as IPO Lisboa) is a highly prestigious public hospital and research center founded on December 29, 1923, as the country’s first comprehensive cancer center. As the primary oncology hub for southern Portugal, the facility manages highly specialized oncology healthcare for a population of nearly five million inhabitants spanning Greater Lisbon, Ribatejo, Alentejo, Algarve, and the autonomous regions of Azores and Madeira. Affiliated with the Portuguese National Health Service (SNS), IPO Lisboa is globally recognized for its pioneering contributions to clinical trials, basic and translational oncology research, its compassionate "patient-first" humanistic care philosophy, and its historical milestone of introducing the region's first structured palliative care and patient residential support infrastructure.

Business Status

Source: Google. OPEN

Business Category

Source: Google. Government hospital

Business Subcategory

Source: Google. Government hospital
Source: Trial-derived.
52Total Trials
Source: Trial-derived.
9Recruiting Trials
Source: Trial-derived.
19Active Trials
Source: Trial-derived.
29Completed Trials
Source: Trial-derived.
55Unique Conditions
Source: Trial-derived.
76Unique Sponsors

Conditions

Source: Trial-derived. Acute Lymphoblastic Leukemia (ALL) (3)Source: Trial-derived. Breast Cancer (3)Source: Trial-derived. Lymphoma (3)Source: Trial-derived. Multiple Myeloma (3)Source: Trial-derived. Carcinoma, Non-Small-Cell Lung (2)Source: Trial-derived. Follicular Lymphoma (2)Source: Trial-derived. Lymphoma, Non-Hodgkin (2)Source: Trial-derived. Mantle Cell Lymphoma (2)

Sponsors

Source: Trial-derived. Hoffmann-La Roche (7)Source: Trial-derived. European Organisation for Research and Treatment of Cancer - EORTC (6)Source: Trial-derived. The Lymphoma Academic Research Organisation (6)Source: Trial-derived. Takeda (4)Source: Trial-derived. Boehringer Ingelheim (3)Source: Trial-derived. Celgene (3)Source: Trial-derived. Australian & New Zealand Children's Haematology/Oncology Group (2)Source: Trial-derived. Centre Hospitalier Universitaire de Nice (2)

Facilities & Operations

Facilities and operational capabilities inferred from trial participation

Source: AI-inferred. Overnight or inpatient research stays supported

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Telehealth study visits

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. CT Scan
Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. Echocardiography
Source: AI-inferred. Full pulmonary function lab (DLCO / plethysmography)
Source: AI-inferred. PET-CT

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Flow Cytometry

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Tumour tissue biopsy (guidance not stated)
Source: AI-inferred. Radiation therapy

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Allogeneic haematopoietic stem cell transplantation
Source: AI-inferred. Bone marrow cytology
Source: AI-inferred. Cellular therapy thawing
Source: AI-inferred. Donor chimerism testing
Source: AI-inferred. Frozen cellular therapy storage
Source: AI-inferred. Haematological cytomorphology
Source: AI-inferred. Interactive response technology
Source: AI-inferred. Intrathecal chemotherapy administration